Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. (NASDAQ: ACON) is a commercial-stage healthcare technology company focused on chronic low back pain, using Magnetic Resonance Spectroscopy (MRS), biomarkers, and augmented intelligence (AI) algorithms to help physicians identify which lumbar discs may be sources of pain. This news page aggregates updates and announcements related to Aclarion’s business, technology, and clinical programs.
Readers can find coverage of Nociscan, Aclarion’s evidence-supported SaaS platform that noninvasively helps distinguish between painful and nonpainful discs in the lumbar spine. News items often highlight scan volume trends across U.S., U.K., and E.U. sites, payer coverage developments such as private insurer reimbursement in the U.K., and the addition of new imaging centers and physician users. These updates provide context on how Nociscan is being adopted in clinical practice.
A key theme in ACON news is clinical evidence generation. Articles describe the pivotal CLARITY trial, a multi-site randomized study evaluating whether incorporating Nociscan into surgical planning can improve outcomes for patients undergoing surgery for chronic low back pain. Other news discusses real-world evidence publications, including cost-effectiveness analyses and case studies published in journals like the International Journal of Spine Surgery, as well as presentations at scientific meetings such as the International Society of Pain and Neuroscience (ISPN).
Financial and corporate developments also feature prominently. Press releases cover equity financings, cash runway updates, and the company’s debt-free balance sheet, along with leadership appointments in finance and commercial roles. Together, these news items offer investors, clinicians, and other stakeholders a consolidated view of Aclarion’s progress in technology development, market expansion, and clinical validation. Users interested in ACON can monitor this page for ongoing announcements related to Nociscan, CLARITY, payer engagement, and broader corporate milestones.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aclarion, a healthcare technology company focused on chronic low back pain, announced significant findings from a clinical trial involving 78 patients. The trial demonstrated an 85% success rate for surgeries targeting discs identified by Nociscan, marking a 22 percentage point improvement over treatments not aligned with Nociscan results (85% vs. 63%; p=0.07). Nociscan, an augmented intelligence platform, measures pain biomarkers without invasive procedures like discography. This two-year durability data, published in the European Spine Journal, emphasizes the platform's potential to aid physicians in optimizing treatment strategies. Aclarion plans to continue clinical trials to further validate these findings and present additional economic benefits at upcoming conferences.
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the appointment of Dr. Alpesh Patel as a key opinion leader (KOL) to enhance its chronic low back pain (CLBP) solution, Nociscan. This marks the eighth advisor in Aclarion's KOL program aimed at strengthening clinical evidence for US commercialization. Nociscan leverages biomarkers and augmented intelligence to assist physicians in identifying pain sources in lumbar discs. Dr. Patel's expertise in spine care is expected to drive significant insights for Aclarion while participating in SPINEWEEK 2023 from May 1-5, 2023.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
